Industry Supported Session

Lunch ’n Learn: New Frontiers in the management of myasthenia gravis

Wednesday, June 7, 2023

12:15 PM – 1:45 PM MST

Location:H-M2: Alberta

Audience:

Adult Neurologist, Child Neurologist, Resident, Fellow, Nurses with interest in myasthenia gravis

Learning Level:

Basic (Resident, New Information), Intermediate (Practicing Physician), Advanced (Special Interest, Higher Level Discussion)

Learning Format:

Forum/panels, Lecture/plenary method, Question and answer session

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Health Advocate, Professional

Faculty(s)

VB

Vera Bril
MM

Michelle Mezei
ZS

Zaeem Siddiqi

Argenx, Canada will host a symposium that will focus on the role IgG regulation through the neonatal Fc receptor (FcRn) blocking: A novel mechanism for the treatment of myasthenia gravis.

This program was developed by the CNSF and argenx Canada, Inc. and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

Understand the evolving treatment landscape for patients with myasthenia gravis
Understand the role of IgG autoantibodies in the pathophysiology of myasthenia gravis
Understand the mechanism of action of efgartigimod
Understand the medical evidence for efgartigimod in the treatment of patients with myasthenia gravis

Presentations:

12:15 PM – 12:20 PM MST

Welcome, Introduction, and Learning Objectives
Faculty: Vera Bril
12:20 PM – 12:35 PM MST

Evolution of the Treatment Landscape and Novel Therapeutic Targets
Faculty: Michelle Mezei
12:35 PM – 12:55 PM MST

Role of IgG Autoantibodies in the Pathophysiology of Myasthenia Gravis
Faculty: Zaeem Siddiqi
12:55 PM – 1:20 PM MST

Review of the Medical Evidence of Efgartigimod for the Treatment of Myasthenia Gravis
Faculty: Vera Bril
1:20 PM – 1:45 PM MST

Faculty Panel Discussion
Faculty: Vera Bril
Faculty: Michelle Mezei
Faculty: Zaeem Siddiqi